

FMHL/SEC/SE/BM/JULY'17

July 25, 2017

The General Manager
Department of Corporate Services
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai – 400 001

Scrip Code: 523696

Sub: Outcome of the Board Meeting

Dear Sir

This is to inform you that the Board of Directors of the Company at their meeting held today i.e. July 25, 2017, *inter-alia*, considered and approved the following:

- a) Un- audited Financial Results of the Company for the quarter ended on June 30, 2017 along with Limited Review Report thereon.
- b) Re-appointment of Dr. Nithya Ramamurthy- Non- Executive Director (DIN: 00255343), who is liable to retire by rotation at the ensuing Annual General Meeting and being eligible offers herself for re-appointment.
- c) Regularization of Mr. Rakesh Laddha (DIN: 06987522) as Director of the Company at the ensuing Annual General Meeting.
- d) Convening of 26th Annual General Meeting of the Company on Tuesday, September 26, 2017 at 10.30 A.M. at National Institute of Pharmaceutical Education and Research, Sector 67, SAS Nagar Mohali- Punjab, 160062.
- e) Further, in terms of Regulation 30, of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the changes in the policy on Determination of Materiality of Event/ Information has been approved by the Board and accordingly the Company has authorized Mr. Meghraj Arvindrao Gore, Whole-time Director, Mr. Vijayasathy D, Chief Financial Officer and Ms. Trapti Kushwaha, Company Secretary - Key Managerial Personnel (KMPs) of the Company for the purpose of determining materiality of an event or information and for the purpose of making disclosures to stock exchange(s). The contact details of KMPs are as given below:

| Name | Designation | Contact Details | E-mail id |
|-----------------------------|-------------------------|-----------------|--|
| Mr. Meghraj Arvindrao Gore. | Whole-time Director | +044 42892222 | secretarial.malar@malarhospitals.com |
| Mr. Vijayasathy D | Chief Financial Officer | | |
| Ms. Trapti Kushwaha | Company Secretary | +0124 4921021 | |



FORTIS MALAR HOSPITALS LIMITED

Regd. Office: Fortis Hospital, Sector 62, Phase – VIII, Mohali-160062
Tel: 0172-5096001 / Fax: 0172-5096002, CIN: L85110PB1989PLC045948

Fortis Malar Hospital

52, First Main Road, Gandhi Nagar, Adyar,
Chennai, Tamil Nadu - 600 020

Tel : +91 44 4289 2222

Fax : +91 44 4289 2293

E-mail: secretarial.malar@malarhospitals.in

Website: www.fortismalar.com


Please find enclosed 'Un- audited Financial Results' of the Company and 'Limited Review Report' thereon for the quarter ended June 30, 2017 along with a copy of the press release being issued in this regard.

The Board Meeting commenced at 01:30 p.m. and concluded at 2:30 p.m.

This is for your information and records please.

Yours faithfully

For Fortis Malar Hospitals Limited



Trapti Kushwaha
Company Secretary
A34747




INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM FINANCIAL RESULTS

TO THE BOARD OF DIRECTORS OF FORTIS MALAR HOSPITALS LIMITED

1. We have reviewed the accompanying Statement of Standalone Unaudited Financial Results of **Fortis Malar Hospitals Limited** ("the Company"), for the Quarter ended June 30, 2017 ("the Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as modified by Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016. This Statement which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to issue a report on the Statement based on our review.
2. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and, accordingly, we do not express an audit opinion.
3. Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the aforesaid Indian Accounting Standards and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as modified by Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For **Deloitte Haskins & Sells LLP**
Chartered Accountants
(Firm's Registration No. 117366W/W-100018)



Sriraman Parthasarathy
Partner
(Membership No. 206834)

Chennai, July 25, 2017
PS/EKP&MS/2017



FORTIS MALAR HOSPITALS LIMITED (CIN: L85110PB1989PLC045948)
 Regd. Office: Fortis Hospital, Sector 62, Phase - VIII, Mohali-160062
 Tel Numbers: 0172 5096001 & Tele Fax No : 0172 5096002
 Website: www.fortismalar.com; Email: secretarial.malar@malarhospitals.in

STATEMENT OF STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2017


(Rs. in Lakhs except EPS)

| No. | Particulars | Standalone | | | |
|-----------|---|------------------------------|---|------------------------------|---|
| | | Quarter ended | | June 30, 2016 (Unaudited) | Year Ended March 31, 2017 (Audited) |
| | | June 30, 2017 (Unaudited) | March 31, 2017 (Audited) (Refer Note 4) | | |
| 1 | Income | | | | |
| | a) Revenue from operations | 3,384.24 | 3,479.48 | 3,301.53 | 14,055.99 |
| | b) Other Income | 185.33 | 192.37 | 180.04 | 756.26 |
| | Total Income | 3,569.57 | 3,671.85 | 3,481.57 | 14,812.25 |
| 2 | Expenses | | | | |
| | a) Purchase of Medical Consumables and Drugs | 738.88 | 606.96 | 717.98 | 2,941.59 |
| | b) Changes in inventories of of Medical Consumables and Drugs | (81.46) | 59.20 | (32.98) | 29.92 |
| | c) Employee Benefits Expense | 538.02 | 509.16 | 471.43 | 1,978.52 |
| | d) Finance Costs | 11.22 | 15.44 | 8.62 | 45.81 |
| | e) Professional Charges to Doctors | 1,063.72 | 1,068.61 | 1,017.11 | 4,236.35 |
| | f) Clinical Establishment Fees | 502.00 | 503.20 | 485.00 | 2,003.17 |
| | g) Depreciation and Amortization Expenses | 100.80 | 99.48 | 93.86 | 394.09 |
| | h) Other Expenses | 728.41 | 774.98 | 628.76 | 2,778.97 |
| | Total Expenses | 3,601.59 | 3,637.03 | 3,389.78 | 14,408.42 |
| 3 | (Loss) / Profit from Ordinary Activities before Tax (1 - 2) | (32.02) | 34.82 | 91.79 | 403.83 |
| 4 | Tax expense | (10.69) | 1.28 | 31.76 | 121.80 |
| 5 | (Loss) / Net Profit from Ordinary Activities After Tax (3-4) | (21.33) | 33.54 | 60.03 | 282.03 |
| 6 | Other Comprehensive (Loss)/Income (net of taxes) | (4.76) | (3.26) | | (24.04) |
| 7 | Total Comprehensive (Loss)/Income for the period (5+6) | (26.09) | 30.28 | 60.03 | 257.99 |
| 8 | Paid up Equity Share Capital (Face Value Rs.10 each) | 1,869.95 | 1,867.95 | 1,862.08 | 1,867.95 |
| 9 | Other Equity | NA | NA | NA | 7,959.97 |
| 10 | Earnings Per Share (EPS) (of Rs. 10 each) | | | | |
| | - Basic | (0.11) | 0.18 | 0.32 | 1.51 |
| | - Diluted | (0.11) | 0.18 | 0.32 | 1.50 |
| | | [not Annualised] | [not Annualised] | [not Annualised] | [Annualised] |

Notes :

- The above unaudited financial results have been reviewed by the Audit and Risk Management Committee, approved and taken on record by the Board of Directors in their meeting held on July 25, 2017. The unaudited results for the quarter ended June 30, 2017 has been subject to limited review by the statutory auditors of the Company.
- The Company operates in a single segment (i.e.) Healthcare Services and hence, does not have any additional disclosures to be made under IND AS 108 - Operating Segments.
- The Board of Directors of the Company at its meeting held on August 19, 2016 approved the proposal for the sale of its hospital business by way of a slump sale to Fortis Healthcare Limited (FHL) pursuant to a composite scheme of Arrangement and Amalgamation between the Company, FHL and SRL Limited ("SRL"). Further, pursuant to the said composite Scheme, the diagnostic business of FHL (including investments held in SRL) shall get demerged into the Company in lieu of equity shares to be issued by the Company to the shareholders of FHL. The demerger shall be followed by SRL being merged with the Company as an integral part of the same composite scheme and shares of the Company to be issued to the eligible shareholders of SRL. The appointed date for the above under the composite scheme is January 1, 2017. The composite scheme of arrangement and amalgamation is subject to various judicial/regulatory and other required approvals. Pending such approvals, no effect of the proposed Scheme has been given in the Financial Results.
- Standalone figures for the quarter ended March 31, 2017 are the balancing figures between the audited figures in respect of the full financial year and the published year to date figures up to the third quarter for the financial year 2016-17.

By Order of the Board
 For and on Behalf of Board of Directors


 D. J. Singh
 Chairman
 DIN No.00135414

Place: Chennai
 Date : July 25, 2017



PRESS RELEASE

FORTIS MALAR REPORTS Q1FY18 REVENUE AT RS. 33.84 CR OPERATING PROFIT FOR THE QUARTER AT RS (-) 1.05 CR

Chennai, Jul 25, 2017: Fortis Malar Hospitals Limited, a subsidiary of Fortis Healthcare Limited, a leading integrated healthcare delivery provider in India, today announced its results for the quarter ended June 30, 2017.

Commenting on the results Mr. Daljit Singh, Chairman, Fortis Malar Hospitals Limited, said, The hospital has been rendering outstanding medical services in Chennai and has been warmly recognized by the public for its contribution to healthcare. It has been doing exceptional work and has achieved the unique distinction of completing over 150 heart transplants, reinforcing its position as a high quality super specialty tertiary care centre in Asia. Additionally, it has made a mark for itself by performing complex and high end surgeries particularly in cardiology, neurology, mother and child care, among others. I am delighted with the great work being done by our team of doctors, nurses, paramedics and other staff members and am confident that we will continue to deliver world class clinical programs, with consistently superior results in the future, as well.”

Financial Highlights for the Quarter (Q1 FY 2018)

- Fortis Malar Hospitals reported operating revenue of Rs 33.84 Cr compared to Rs 33.01 Cr reported in the corresponding quarter of the previous year, a growth of 3%.
- Operating profit for the quarter stood at Rs (-) 1.05 Cr compared to Rs 0.14 Cr in the corresponding quarter of previous year.
- Profit before tax stood at Rs. (-) 0.32 Cr compared to Rs. 0.92 Cr in corresponding quarter of previous year.
- Net profit for the quarter was at Rs (-) 0.26 Cr compared to Rs. 0.60 Cr in the corresponding quarter of previous year.
- During the quarter, Fortis Malar witnessed growth in its key specialties such as Cardiothoracic & Vascular Surgery (CTVS), Neuro, Allied Surgical Specialty and Renal which grew by 74%, 54%, 69%, and 20% respectively compared to the corresponding quarter of previous year.

Operational Highlights for the quarter

- **THE FORTIS CENTER FOR HEART FAILURE & TRANSPLANT** has successfully completed over 150 heart transplants, 12 long-term left ventricular assist devices (LVAD) and 45 Veno arterial ECMOs for critical heart failure. The center is also credited with India's first successful implantation of Heartmate II LVAD and HVAD mechanical artificial heart pumps and the first to successfully use ECMO to resuscitate patients from cardiac arrest. The center has also performed numerous inter-state heart retrievals for transplantation and has one of the largest series of Pediatric heart transplants in the country including a young infant of 1 year weighing 6 Kg. The outcomes of transplants are excellent with a one year survival of over 90 % in these critically ill patients.
- In a first-of-its kind transplant surgery, a team of senior doctors from Fortis Malar Hospital conducted a successful bilateral lung transplant on twenty one year old Ukrainian patient, who was critically ill due to pulmonary hypertension in lungs. The challenging surgery of transplanting a pair of new lungs was performed by the team led by Dr. K R Balakrishnan, Director, Cardiac Sciences and Dr. Suresh Rao K G, HOD Critical Care & Cardiac Anesthesia. The patient was diagnosed with pulmonary hypertension and high lung blood pressure; due to the pulmonary hypertension the heart's right ventricle started to function below the optimal level. The experts at Fortis Malar Hospital performed the transplant surgery to help the patient recover.
- Symposium on CRRT (Continuous Renal Replacement Therapy) - The clinical picture of Renal dysfunction, Fluid overload and Sepsis are not uncommon in Critical Care set-ups. Kidney is a sensitive organ that can take a hit and go for acute renal failure in critically ill patients of any etiology. Acute renal failure exacerbates the mortality and morbidity. Among the various techniques of renal replacement therapy, CRRT stands unique in view of its numerous advantages. The therapeutic benefits of CRRT are applicable not only in renal failure, but also in diverse clinical scenarios. The utility of CRRT in Sepsis is an emerging and promising application.

Corporate Social Responsibility

As a responsible corporate citizen, Fortis Malar has been involved in activities that contribute to society. The following CSR activities were undertaken during the quarter:

- Fortis Malar Hospital observed World Malaria Day by cleaning up Malligai Poo Nagar a (adopted by Fortis Malar hospital) slum in Chennai's Adyar locality, home for over 1000 people.
- As a part of Fortis Seva Trust's Swachh Fortis CSR program, Fortis Malar Hospital staff worked along with the volunteers in these areas to remove garbage from the

streets and residential areas for a clean living environment of the residents. Post cleaning mosquito repellent was sprayed across the slum area. As part of the green initiative, saplings were distributed to the people, followed by a hand hygiene session conducted by infection control nursing staff. These activities raised awareness amongst the residents on the importance of a cleaner environment and improving their hygiene. About 50 Volunteers took up the task of cleaning solid and liquid waste in the slum as a part of this cleaning initiative. They also painted the walls with cleanliness messages written on it in an effort to make slum-dwellers understand the need to keep their area clean and hygienic and to help in fight against Malaria – which is a completely preventable disease.

About Fortis Malar Hospitals Ltd

Fortis Malar Hospital (formerly known as Malar Hospital) was acquired by Fortis Healthcare (India) Limited in early 2008. The hospital founded in 1992, is established as one of the largest corporate hospitals in Chennai providing quality super specialty and multi-specialty healthcare services. Fortis Malar Hospitals, with 180 beds, focuses on providing comprehensive medical care in the areas of Cardiology and Cardiac Surgery, Neuro Surgery, Gynaecology, Orthopaedics, Gastroenterology, Neurology, Paediatrics, Diabetics, Nephrology and Internal Medicine.

Fortis Malar Hospital has a state of the art Cath Lab and multiple dedicated cardiac operation theatres and intensive coronary care units. Several rare and complex Adult and Paediatric Cardiac surgeries, Orthopedic and Joint replacements, Neurosurgeries and Plastic reconstruction surgeries have been performed at this hospital. The hospital's Obstetrics and Gynaecology services are among the busiest in the city, successfully performing many complicated deliveries and surgeries. They are supported by a dedicated Neonatology unit.

About Fortis Healthcare Ltd

Fortis Healthcare Limited is a leading integrated healthcare delivery service provider in India. The healthcare verticals of the company primarily comprise hospitals, diagnostics and day care specialty facilities. Currently, the company operates its healthcare delivery services in India, Dubai, Mauritius and Sri Lanka with 45 healthcare facilities (including projects under development), approximately 10,000 potential beds and over 360 diagnostic centres.

DISCLAIMER

This press release may contain forward-looking statements based on the currently held beliefs and assumptions of the management of the Company, which are expressed in good faith and, in their opinion, reasonable. Forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause the actual results, financial condition, performance, or achievements of the Company results, to differ materially from the results, financial condition, performance or achievements expressed or implied by such forward-looking statements. Given these risks, uncertainties and other factors, recipients of this press release are cautioned not to place undue reliance on these forward-looking statements. The Company assumes no responsibility to publicly amend, modify or revise any forward looking statements, on the basis of any subsequent development,

information or events, or otherwise. The information contained herein is subject to change without notice and past performance is not indicative of future results. The Company may alter, modify or otherwise change in any manner the content of this press release, without obligation to notify any person of such revision or changes.

FOR MORE INFORMATION PLEASE CONTACT

Rajarishi / Seetha.C
PR & Communications
Fortis Malar Hospitals Ltd
Mobile: 9176988775
seetha.c@fortishealthcare.com

Sumit Jain
K2 Communications Pvt Ltd
Mobile: 9886021715
Sumit.jain@k2communications.in